Expert Review of Pharmacoeconomics & Outcomes Research

Article	Citations
A landscape analysis and discussion of value of gene therapies for sickle cell disease	48
Adherence to augmentation therapy for the treatment of major depressive disorder	38
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	26
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	23
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature	20
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	20
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	18
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	17
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	16
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study	15
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	15
Social care data in the UK; current landscape, challenges, and future recommendations	14
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	13
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	13
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review	12
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	12
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	11
The cost-of-illness of multiple sclerosis in Jordan	11
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	11
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	10
Addressing racial/ethnic disparities associated with Medicare Part D Star Ratings among population with Alzheimer’s disease and related dementias	10
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	10
Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review	10
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	9
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	9

Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	9
How to create value with constrained budgets in oncological care? A narrative review	9
Cost-effectiveness of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing device for treatment of heavy menstrual bleeding: a systematic review	9
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	9
The hidden burden of atopic dermatitis in central and Eastern European countries	9
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	8
Challenges and opportunities in measuring the pediatric quality of life: exemplified by research in pediatric gastroenterology	8
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	8
Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database	8
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	8
Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review	8
Hospital care of endometriosis in Spain: a retrospective multicenter analysis of patient characteristics and costs	7
Evaluating the correlations of cost and utility parameters from summary statistics for probabilistic analysis in economic evaluations	7
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	7
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis	7
A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer	7
Disparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States	7
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	7
Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study	7
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain	7
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review	7
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?	6
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer	6
Content and cost of waste pharmaceuticals collected by pharmacies for disposal	6
Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme	6
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	6
Not cost-effective at zero price: valuing and paying for combination therapies in cancer	6
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	6
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	6
Interview with Julie Frappier, health economist, and creator of the TOWWERS™ System	6
Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency	5
Nonadherence to antiseizure medications: what have we learned and what can be done next?	5
Assessing the economic impact of digital endpoints on medication adherence	5
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	5
Economic benefits of global Collaborative Health technology	5
Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic review	5
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden	5
Natural language processing – relevance to patient outcomes and real-world evidence	5
What to expect in 2024: important health economics and outcomes research (HEOR) trends	5
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	5
Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
The long-term clinical impact of digital endpoints and biomarkers in data collection	4
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	4
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	4
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications	4
Distinguishing features in the assessment of mHealth apps	4
Canadian English translation and linguistic validation of the 13-MD to measure global health-related quality of life	4
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	4
Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument	4

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation	4
Description of characteristics, management of care and healthcare direct costs of patients with HR+/HER2- early breast cancer in Italy: a real-world study involving administrative and pathological ana	4
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	4
The utility and impact of digital endpoints for improving breast cancer outcomes	4
Can we achieve affordable cancer medicine prices? Developing a pathway for change	4
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	4
Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension	4
The role of insurance policies in the drug pricing landscape	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer	4
Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study	4
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	4
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	4
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia	4
Coping with increasing medicine costs through greater adoption of generic prescribing and dispensing in Pakistan as an exemplar country	4
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study	4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	3
A visual approach to the economic evaluation of vaccines: opening the health economic black box	3
Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review	3
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A	3
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	3
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer	3
Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil	3
Evaluation instruments for executive functions in children and adolescents: a systematic review	3
Canadian French translation and linguistic validation of the health-related quality of life utility measure for pre-school children	3
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	3
Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence	3
An early cost analysis of magnetic bone growth stimulation in England	3
Measuring valued output in primary care: challenges and reconciliation	3
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause	3
Economic burden of depression in Brazil: a cost-of-illness study based on productivity losses and healthcare costs between 2010 to 2018	3
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	3
Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia	3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	3
Health-related quality of life measured using the EQ-5D-3L: iranian population norms	3
An early health technology assessment of 3D anatomic models in pediatric congenital heart surgery: potential cost-effectiveness and decision uncertainty	3
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	3
Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms	3
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	3
Artificial intelligence in outcomes research: a systematic scoping review	3
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury	3
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis	3
Burden of disease and costs of infections associated with cardiac implantable electronic devices	3
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach	3
Consumption of antidepressants and economic austerity in Brazil	3
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study	3
A systematic review of cost-effectiveness analyses across the acute kidney injury landscape	2
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies	2
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	2
Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study	2
Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis	2
Correction	2
Psychometric properties of the Polish version of SF-12v2 in the general population survey	2
Mapping the schizophrenia quality of life scale to EQ-5D, HUI3 and SF-6D utility scores in patients with schizophrenia	2
Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada	2
Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?	2
Burden of disease of spinal muscular atrophy linked to chromosome 5q (5q-SMA) in Colombia	2
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	2
The impact of under-investment on health in Southern and Central Eastern European Countries	2
Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step	2
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments	2
Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach	2
Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study	2
Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review	2
Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy	2
Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma	2
Systematic reviews of machine learning in healthcare: a literature review	2
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	2
Cost-related nonadherence for prescription medications: a cross-sectional study in Jordan	2
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	2
Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update	2
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	2
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	2
Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand	2
Correction	2
Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control	2
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review	2
Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals	2
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	2
Predictors of 30-day readmission, mortality, and length of stay for hospitalized U.S. patients with Alzheimer’s and related dementias from 2010 to 2015	2

The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	2
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	2
Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis	2
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	2
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health	2
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension	2
An update on the economic burden of type 2 diabetes mellitus in China	2
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023	2
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	2
Work productivity among patients with metastatic breast cancer in the United States	2
An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis	2
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention	2
Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990–2022	2
Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia	2
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review	2
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review	2
Technologies and decision-support tools for health systems management: a scoping review of features and use cases	2
Implementing a Managed Entry Agreement Framework in Cyprus	2
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)	2
A methodological guide for implementing and interpreting results of probabilistic analysis	2
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	2
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	2
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	2
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain	2
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	2
Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study	2
Cost considerations of dermatological care in Jordan: a cross-sectional study	2
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	2
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer	2
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	2
Imputing missing patient-level data and propensity score matching in cost-effectiveness analysis in Crohn's disease	2
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	2
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore	2
Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia	1
Disease and economic burden of surgery in desmoid tumors: a review	1
HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework	1
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	1
Identification of cognitively impaired patients at risk for development of Alzheimer’s disease dementia: an analysis of US Medicare claims data	1
How can environmental impacts be incorporated in health technology assessment, and how impactful would this be?	1
Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma	1
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications	1
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore	1
Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience	1
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Sing	1
First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis	1
Multiple sclerosis: economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region	1
Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal	1
Digital measures in epilepsy in low-resourced environments	1
Economic burden associated with stroke in India: insights from national sample survey 2017-18	1
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	1
Chronic inflammatory demyelinating polyneuropathy in Spain: a retrospective analysis of hospital incidence and medical costs	1
Economic evaluation of clinical pharmacy service using integrated health system in tertiary care hospital	1
Monetary valuation of one year in full capability and health based on demographics, health status, income and well-being	1
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial	1
Perspectives in prospective comparative economic evaluations: a systematic review	1
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	1
Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia	1
Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study	1
Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States	1
Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies	1
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	1
Budget impact analysis of medicines: estimated values versus real-world evidence and the implications	1
The economic impact of pharmacist intervention during pandemics	1
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	1
Pharmacoeconomics of obesity in China: a scoping review	1
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	1
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	1
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?	1
The costs of treatment resistant depression: evidence from a survey among Italian patients	1
Evaluation of Antimicrobial Stewardship Programs and antibiotic prescribing patterns among physicians in ambulatory care settings in Jordan	1
Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor	1
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health syst	1
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	1
Design and testing of a health economic Markov model for treatment of anorexia nervosa	1
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	1
A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials	1
Performance-based risk-sharing agreements in renal care: current experience and future prospects	1
Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China	1
Cost-effectiveness of stereotactic body radiotherapy in the treatment of non–small-cell lung cancer (NSCLC): a systematic review	1
A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population	1
Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures	1
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	1
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspe	1
How should we measure the use of social care and informal care?	1
Burden of disease of chronic pain in Colombia	1
Accounting for inflation within NICE cost-effectiveness thresholds	1
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore	1
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events	1
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China	1
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer	1
Payer and Developer perspectives on alternative payment models	1
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer	1
Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment	1
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	1
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder	1